GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

parunoflast   Click here for help

GtoPdb Ligand ID: 14415

Synonyms: Compound 17B [WO2023178099]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for this compound was obtained from WHO INN proposed list 134 (Feb 2026), in which it is described as a NOD-like receptor pyrin domain-containing 3 (NLRP3) inflammasome inhibitor with potential as a non-steroidal anti-inflammatory agent. It is one of the structures claimed in Zomagen Biosciences' (now part of Eli Lilly via a previous Ventyx Biosciences merger) patent WO2023178099 [1]. Evidence suggests that parunoflast is likely the INN for the CNS-penetrant NLRP3 inhibitor VTX3232.
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 5
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 68.42
Molecular weight 381.39
XLogP 2.89
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CC1=C(C2=C(C=C(C=C2)C(F)(F)F)O)N=NC(=C1)[C@@H]([C@@H]3CCCN(C)C3)O
Isomeric SMILES O[C@@H](C1=CC(=C(N=N1)C2=C(C=C(C=C2)C(F)(F)F)O)C)[C@H]3CN(CCC3)C
InChI InChI=1S/C19H22F3N3O2/c1-11-8-15(18(27)12-4-3-7-25(2)10-12)23-24-17(11)14-6-5-13(9-16(14)26)19(20,21)22/h5-6,8-9,12,18,26-27H,3-4,7,10H2,1-2H3/t12-,18-/m1/s1
InChI Key RWDYJVRIDGIICC-KZULUSFZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
VTX3232 was progressed as a clinical candidate for the treatment of Parkinson disease and chronic inflammation associated with cardiovascular risks in obesity.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT06556173 Phase 2a Study of VTX3232 in Parkinson's Disease Phase 2 Interventional Zomagen Biosciences Ltd.
NCT06771115 Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in Obesity Phase 2 Interventional Zomagen Biosciences Ltd.